PODD Insulet Corporation
company
SEC Filings & Insider Trading Activity 2026

CIK: 1145197
Health Care
Surgical & Medical Instruments & Apparatus 53 filings
S&P 500

Latest Insulet Corporation (PODD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 18, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Insulet Corporation (PODD) (SEC CIK 1145197), with AI-powered section-by-section summaries updated daily.

10-Q: 33
10-K: 12
8-K: 8

Latest 2026 SEC Filing Dates

10-K Annual Report
Feb 18, 2026
10-Q Quarterly Report
Nov 6, 2025
8-K Current Report
Apr 29, 2026

AI 10-K Annual Report Analysis
Latest 10-K (2025-12-31)

Management Discussion & Analysis

  • Revenue $2,708.1M in 2025, up 30.7% YoY (+$636.6M); U.S. revenue $1,919.8M (+27.2%), International $754.3M (+44.1%)
  • Gross margin 71.6% in 2025 vs 69.8% in 2024; R&D expense 11.1% of revenue vs 10.6%; SG&A 43.0% vs 44.3%
+3 more insights

Business Overview

  • Core business in marketing and product training within healthcare, focusing on compliance with complex healthcare laws like Medicare, Medicaid, and anti-bribery statutes
  • Emphasis on advanced AI tool deployment and adherence to evolving global privacy, data protection, and AI regulations including EU AI Act by August 2026
+3 more insights

Risk Factors

  • Cybersecurity risk oversight primarily by NGR Committee with regular updates from CISO and strategic roadmap reviews
  • CISO reports to CTO, leading cybersecurity program including risk detection and continuous improvement in medical device manufacturing
+2 more insights

AI 10-Q Quarterly Report Analysis
Latest 10-Q (2025-09-30)

Management Discussion & Analysis

  • Revenue $706.3M for Q3 FY2025, up 29.9% YoY from $543.9M in Q3 FY2024; Omnipod Products revenue up 31.0% to $699.2M
  • Gross margin improved to 72.2% in Q3 FY2025 from 69.3% YoY; Cost of revenue 27.8% vs 30.7% of revenue

Risk Factors

  • New risk: Potential U.S. tariff expansion under Section 232 investigation on medical devices triggered September 24, 2025 BIS probe
  • No material updates to previously disclosed risks from 2024 10-K reported
Read full Q3 2025 10-Q analysis →

AI 8-K Current Report Analysis
Recent 8-K Filings

Filed Mar 12, 2026
8-K
Full analysis →

Item 7.01: Regulation FD Disclosure

  • Insulet ($PODD) initiated a voluntary medical device correction — signals a product safety/quality issue with its insulin delivery devices
  • FDA involvement flagged as a key risk — future regulatory actions could expand scope or impose additional requirements beyond voluntary correction
Filed Mar 4, 2026
8-K
Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Former CFO Ana M. Chadwick's severance agreement finalized Feb 27, 2026 — no new compensation terms beyond previously disclosed arrangements
  • Severance terms governed by Amended and Restated Executive Severance Plan (filed Apr 28, 2025) and prior Sep 16, 2025 8-K disclosures

Annual Reports Archive
10-K

AI-powered analysis of Insulet Corporation (PODD) 10-K annual reports filed with SEC EDGAR.

Quarterly Reports Archive
10-Q

AI-powered analysis of Insulet Corporation (PODD) 10-Q quarterly reports filed with SEC EDGAR.

Recent 8-K Filings
Current Reports

AI-powered analysis of Insulet Corporation (PODD) 8-K current reports disclosing material events.

Financial Summary
XBRL

FY2022FY2023FY2024FY2025
Profitability
Revenue$1.3B$1.7B$2.1B$2.7B
Gross Profit$805.6M$1.2B$1.4B$1.9B
Operating Income$220.0M$308.9M$473.8M
Net Income$206.3M$418.3M$247.1M
Gross Margin61.7%68.3%69.8%71.6%
Op. Margin13.0%14.9%17.5%
Net Margin12.2%20.2%9.1%
Balance Sheet
Total Assets$2.6B$3.1B$3.2B
Equity$732.7M$1.2B$1.5B
ROE28.2%34.5%16.3%

Source: XBRL financial data from Insulet Corporation (PODD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Apr 29, 2026
8-K
Mar 12, 2026Analysis
8-K
Mar 4, 2026Analysis
8-K
Feb 24, 2026Analysis
10-K
Feb 18, 2026Dec 31, 2025Analysis
8-K
Feb 18, 2026
8-K
Feb 3, 2026
8-K
Dec 19, 2025
8-K
Dec 17, 2025
10-Q
Nov 6, 2025Sep 30, 2025Analysis
10-Q
Aug 7, 2025Jun 30, 2025Analysis
10-Q
May 9, 2025Mar 31, 2025Analysis
10-K
Feb 21, 2025Dec 31, 2024
10-Q
Nov 8, 2024Sep 30, 2024
10-Q
Aug 9, 2024Jun 30, 2024
10-Q
May 10, 2024Mar 31, 2024
10-K
Feb 23, 2024Dec 31, 2023
10-Q
Nov 3, 2023Sep 30, 2023
10-Q
Aug 9, 2023Jun 30, 2023
10-Q
May 5, 2023Mar 31, 2023
10-K
Feb 24, 2023Dec 31, 2022
10-Q
Nov 4, 2022Sep 30, 2022
10-Q
Aug 5, 2022Jun 30, 2022
10-Q
May 6, 2022Mar 31, 2022
10-K
Feb 24, 2022Dec 31, 2021

Frequently Asked Questions

What are the latest PODD SEC filings in 2026?

Insulet Corporation (PODD) has filed a 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PODD file its most recent 10-K annual report?

Insulet Corporation (PODD) filed its most recent 10-K annual report on February 18, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PODD 10-Q quarterly reports?

Insulet Corporation (PODD)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every PODD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PODD filed recently?

Insulet Corporation (PODD)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PODD insider trading activity (Form 4)?

SignalX aggregates every PODD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PODD file with the SEC?

Insulet Corporation (PODD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PODD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Insulet Corporation (PODD).

What is PODD's SEC CIK number?

Insulet Corporation (PODD)'s SEC CIK (Central Index Key) number is 1145197. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1145197 to look up all PODD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PODD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Insulet Corporation (PODD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of Insulet Corporation SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 53+ filings.